UNSPSC 51352405: Drospirenone/ethinyl estradiol

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS200. This VA Drug Class (HS200) classifies this compound as belonging to the group CONTRACEPTIVES, SYSTEMIC.

UNSPSC 51352405 Drospirenone/ethinyl estradiol is a Commodity code that covers birth control pill formulations containing this active ingredient combination. State and local governments procure this pharmaceutical through pharmacy benefit programs, cooperative purchasing alliances, and health plans serving employees, retirees, and eligible populations. The solicitations under this code demonstrate procurement through both direct-to-manufacturer models and traditional multi-source generic pharmaceutical contracts that bundle drospirenone/ethinyl estradiol with broader formulary offerings. Issuing bodies include state health and human services departments, state procurement offices administering cooperative purchasing alliances, and participating municipal and county health facilities accessing contracts through those alliances. The code reflects procurement activity driven by state-level pharmacy benefit strategy and the need for competitive pricing on commonly dispensed contraceptive medications.

Recent activity centers in Texas and Minnesota. The Texas Health and Human Services Commission issued RFI HHS0017013 (posted April 3, 2026, response due April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling the state's intent to establish direct relationships with pharmaceutical manufacturers outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 (posted January 20, 2026, response due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, with drospirenone/ethinyl estradiol included in the broader product set. The MMCAP RFP requires supply through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC), with award effective July 1, 2026, and includes participating Oregon facilities alongside Minnesota state and local agencies. Evaluation emphasizes price competitiveness (75 percent weight) and compliance with cGMP and Drug Supply Chain Security Act requirements. Vendors must maintain commercial general liability insurance of $5,000,000 per occurrence and accept a 3 percent administrative fee on all contract purchases.